InsidersTradesSigma
申报总数
公司
▲ 买入（0 笔）
▼ 卖出（0 笔）
内部人交易记录
高级管理人员已披露买入
0
已披露卖出
0
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
信号历史
无可用的信号评分。
Discover the complete record of transactions filed by Walbert Keli, Director. Director active across 2 companies, notably Apellis Pharmaceuticals, Inc.. In total, 3 reports have been logged. History available since 8 January 2025. The latest transaction was filed on 1 January 2026 (Attribution). Regulator: SEC (Form 4). The full history is openly available.
Companies and markets linked to Walbert Keli
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报3 总计
17,051 股Common StockSEC:0001193125-26-224601:0
7,961 股0Common StockSEC:0001492422-26-000009:0
9,090 股0Common StockSEC:0001127602-25-001073:0
3 条申报中的 3 条
About Walbert Keli
Keli Walbert is a Board Member at Apellis Pharmaceuticals, Inc. She brings significant expertise in corporate governance and strategy. In her role, Keli oversees operations and contributes to strategic decision-making for the company. Her experience in the pharmaceutical sector is an asset for Apellis.
